Related Experiment Video
Updated: Jun 17, 2026
Knockdown of FAM83A to Verify Its Role in Cervical Cancer Cell Growth and Cisplatin Sensitivity
Published on: February 9, 2024
Silencing Fas-associated phosphatase 1 expression enhances efficiency of chemotherapy for colon carcinoma with
Zhi-Yu Xiao1, Wei Wu, Navada Eagleton
1Department of Surgery, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Guangzhou 510120, Guangdong Province, China.
Aim:
To investigate whether silencing Fas-associated phosphatase 1 (FAP-1) expression enhances the efficiency of chemotherapy for colon carcinoma with oxaliplatin.
Methods:
Expression of FAP-1 in mRNA and protein was detected by reverse transcription polymerase chain reaction (RT-PCR) and flow cytometry. Small interfering RNA (siRNA) was designed according to the FAP-1 mRNA sequence. Cell proliferation was evaluated by methyl thiazolyl tetrazolium (MTT) assay. Anenxin V- and propidine iodine (PI) were assayed by flow cytometry for the detection of apoptosis.
Results:
The expression of FAP-1 was increased in SW480 cells after chemotherapy with oxaliplatin. Transfection of FAP-1 siRNA into SW480 cells silenced the expression of FAP-1 and consequently abolished the inhibitory function of Fas/FasL-mediated apoptosis pathway, thus increasing the efficacy of chemotherapy for colon carcinoma with oxaliplatin.
Conclusion:
RNA interference combined with conventional chemotherapy is more effective against colon cancer.
Insights
Silencing Fas-associated phosphatase 1 (FAP-1) in colon cancer cells increases oxaliplatin chemotherapy effectiveness. Combining RNA interference with chemotherapy offers a more potent treatment strategy for colon cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Fas-associated phosphatase 1 (FAP-1) plays a role in cellular signaling pathways.
- Oxaliplatin is a common chemotherapeutic agent used for colon carcinoma.
- Understanding mechanisms to enhance chemotherapy efficacy is crucial for improving patient outcomes.
Purpose of the Study:
- To determine if silencing FAP-1 enhances oxaliplatin chemotherapy efficacy in colon carcinoma.
- To investigate the role of FAP-1 in the response to oxaliplatin treatment.
Main Methods:
- FAP-1 expression was quantified using RT-PCR and flow cytometry.
- Small interfering RNA (siRNA) was utilized to silence FAP-1 expression.
- Cell proliferation and apoptosis were assessed via MTT assay and flow cytometry (Annexin V/PI staining).
Main Results:
- Oxaliplatin treatment increased FAP-1 expression in SW480 colon cancer cells.
- FAP-1 siRNA transfection successfully reduced FAP-1 expression.
- Silencing FAP-1 enhanced oxaliplatin's anti-cancer effects by modulating the Fas/FasL-mediated apoptosis pathway.
Conclusions:
- RNA interference targeting FAP-1 combined with oxaliplatin chemotherapy demonstrates superior efficacy against colon cancer.
- This combination therapy presents a promising approach for treating colon carcinoma.
